As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: February 25, 2012
by Traci Pedersen for Psych Central
Alzheimer’s medications currently in trial may actually act like a bad electrician, miswiring neurons and interfering with their ability to communicate with the brain, according to new Northwestern Medicine research.
The problematic side effects were found by Robert Vassar, the scientist whose original study led to the development of the drugs designed to inhibit BACE1—the enzyme Vassar discovered that promotes plaque development. BACE1 is likened to a pair of molecular scissors, cutting up and releasing proteins that form plaque. Therefore, drug developers thought that if the enzyme were blocked, the disease would slow down.
“Let’s proceed with caution,” said Vassar, professor of cell and molecular biology at Northwestern University Feinberg School of Medicine. “We have to keep our eyes open for potential side effects of these drugs.” Ironically, he says, the drugs could impair memory.
In Vassar’s new study, he discovered that BACE1 also plays a critical role as the brain’s electrician. Specifically, the enzyme maps out the location of axons, the wires that connect neurons to the brain and the nervous system. This mapping is known as ‘axonal guidance.’
Studying mice from which BACE1 was genetically removed, Vassar discovered that the axons in the rodents’ olfactory system – used for the sense of smell—were not wired properly to the olfactory bulb of the brain. The research proved the role of BACE1 in axonal guidance.
“It’s like a badly wired house,” Vassar said. “If the electrician doesn’t get the wiring pattern correct, your lights won’t turn on and the outlets won’t work.”
If the axons aren’t correctly connected in the olfactory system, Vassar said, the problem probably exists elsewhere in the brain and nervous system. For example, the hippocampus could be especially vulnerable to BACE1 blockers, he added, because its neurons are continually being reborn, which may play a role in forming new memories. The neurons must grow new axons which will connect them with new targets. Axonal guidance is a continuous need.
“It’s not all bad news,” Vassar noted. “These BACE1 blockers might be useful at a specific dose that will reduce the amyloid plaques but not high enough to interfere with the wiring. Understanding the normal function of BACE1 may help us avoid potential drug side effects.”
The research is published in the journal Molecular Neurodegeneration.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.